Eagle Pharmaceuticals, Inc.
EGRX · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Revenue | $64,646 | $66,305 | $60,699 | $65,901 |
| % Growth | -2.5% | 9.2% | -7.9% | – |
| Cost of Goods Sold | $16,858 | $17,300 | $19,866 | $23,651 |
| Gross Profit | $47,788 | $49,005 | $40,833 | $42,250 |
| % Margin | 73.9% | 73.9% | 67.3% | 64.1% |
| R&D Expenses | $9,833 | $9,272 | $7,217 | $9,326 |
| G&A Expenses | $23,251 | $24,260 | $20,750 | $21,762 |
| SG&A Expenses | $27,651 | $27,960 | $24,150 | $23,462 |
| Sales & Mktg Exp. | $4,400 | $3,700 | $3,400 | $1,700 |
| Other Operating Expenses | $0 | -$238 | $0 | $0 |
| Operating Expenses | $37,484 | $37,232 | $31,367 | $32,788 |
| Operating Income | $10,304 | $6,187 | $9,466 | -$2,306 |
| % Margin | 15.9% | 9.3% | 15.6% | -3.5% |
| Other Income/Exp. Net | -$1,006 | -$1,542 | $3,838 | -$1,357 |
| Pre-Tax Income | $9,298 | $10,231 | $13,304 | -$45 |
| Tax Expense | $4,134 | $4,481 | $5,139 | $3,468 |
| Net Income | $5,164 | $5,750 | $8,165 | -$3,513 |
| % Margin | 8% | 8.7% | 13.5% | -5.3% |
| EPS | 0.39 | 0.44 | 0.63 | -0.27 |
| % Growth | -11.4% | -30.2% | 333.3% | – |
| EPS Diluted | 0.39 | 0.44 | 0.62 | -0.27 |
| Weighted Avg Shares Out | 13,091 | 13,059 | 13,016 | 13,167 |
| Weighted Avg Shares Out Dil | 13,155 | 13,153 | 13,124 | 13,167 |
| Supplemental Information | – | – | – | – |
| Interest Income | $195 | $212 | $317 | $0 |
| Interest Expense | $1,448 | $1,516 | $1,980 | $1,591 |
| Depreciation & Amortization | $5,580 | $5,893 | $5,956 | $4,224 |
| EBITDA | $16,326 | $17,307 | $21,194 | $2,152 |
| % Margin | 25.3% | 26.1% | 34.9% | 3.3% |